Celltrion Wins Tender in Belgium Alongside Original Manufacturer BayerAccording to the Official Journal of the European Union (TED) on the 17th
,Celltrion Healthcare’s Dutch subsidiary won two categories in the tender for the supply of aflibercept at St. Lucas General Hospital in Belgium
,which was announced on the 9th.
Celltrion was selected as the supplier for both the prefilled syringe (PFS-S) and vial categories of aflibercept for adult ophthalmic conditions. This product corresponds to Celltrion’s Eylea biosimilar, “Idenzelt.”
This tender is a contract to secure aflibercept for use at St. Lucas Hospital in Ghent, Belgium, and regional hospitals in Bruges. Aflibercept is the active ingredient in Bayer’s “Eylea,” a treatment for ophthalmic diseases, and is used for wet age-related macular degeneration, diabetic macular edema, macular edema due to retinal vein occlusion, and myopic choroidal neovascularization.
In the same procurement notice, the Belgian subsidiary of Bayer—the developer of the original Eylea—was also selected as a supplier in a separate category. Observers note that it is significant that Celltrion was partially selected in a bid in which the original drug developer participated.
Celltrion’s winning bid amount for the PFS-S category was 2,444,000 euros, and for the vial category, 10,660 euros, for a total of 2,454,660 euros. The base contract term is two years, and the contracting authority may extend the contract twice, for one year each time. This means that if all extension options are exercised, supply can continue for up to four years. In this case, the contract ceiling for the prefilled syringe segment is 5,696,400 euros, and for the vial segment, it is 98,400 euros.
The contract was signed on the 29th of last month, and the supply start date was set for the 1st of this month. Since the timing of revenue recognition depends on actual shipment volumes and delivery dates, the scale of shipments following the start of supply will be crucial.
From Belgium’s “Aptozma” to Germany’s “Omliclo”Celltrion has also entered the Belgian hospital group purchasing market with “Aptozma,” a biosimilar of Actemra (active ingredient: tocilizumab).
In a tocilizumab tender conducted by the Belgian hospital consortium Hospilim VZW, Celltrion Healthcare’s Dutch subsidiary was selected as the supplier. Hospilim is a hospital consortium formed by hospitals in the Limburg region of Belgium to jointly purchase pharmaceuticals and medical services.
The tender notice was published on the 2nd. The contract signing date is September 21, and the basic contract term is 24 months. Two companies participated in the tender. The procurement target is a single product: tocilizumab. The maximum limit for the basic contract was listed at 577,755 euros.
Celltrion also launched Aptosma in Japan for the first time this year. In Europe, the company has secured an additional supply base through the hospital channel via this Belgian hospital consortium tender.
In Germany, Celltrion Healthcare’s German subsidiary secured the right to supply “Omriclo,” a treatment for allergic diseases, to hospital pharmacies. Omriclo is a biosimilar of Novartis’s Xolair (active ingredient: omalizumab).
In the omalizumab tender conducted by PBMG eG—which manages joint procurement for German hospital pharmacies and medical institutions—Celltrion was selected as the supplier for all three dosages: 75 mg, 150 mg, and 300 mg. This lays the groundwork for expanding supply across the entire hospital channel, rather than being limited to specific indications or certain formulations.
The supply period is one year, from July 1 of next year through June 30, 2028. The contract value and planned supply volume were not disclosed.
The Key to Entering the European Market… Tailored Local ‘Direct Sales Infrastructure’This contract win is characterized by direct supply through hospitals or hospital group purchasing organizations. In the European pharmaceutical market, hospital procurement methods, health insurance reimbursement systems, and bidding procedures vary by country. This means that after a product is approved, Celltrion must participate in country-specific procurement procedures and propose prices and supply terms tailored to the needs of hospitals and purchasing organizations in order to generate actual sales.
To address these market characteristics, Celltrion operates direct sales systems through local subsidiaries in major European countries. The company leverages the network of medical institutions and purchasing organizations established while selling existing products, along with its experience in participating in tenders and market-specific distribution and supply know-how, to facilitate the market entry of new products.
A Celltrion official stated, “It is difficult to disclose details regarding our specific sales activities, such as tenders,” but added, “We have built a robust local direct sales network and sales infrastructure in Europe through our long-standing supply of biosimilar products.”
The spokesperson continued, “We are actively leveraging the networks with local medical institutions and purchasing organizations, experience in participating in tenders, and market-specific distribution and supply know-how accumulated through the sales of our existing products to facilitate the market entry of new products,” adding, “We plan to continue delivering results based on this direct sales infrastructure and local sales capabilities.”
Celltrion is expanding its biosimilar portfolio beyond its existing lineup—which focuses on autoimmune diseases and anticancer drugs—to include ophthalmic diseases, allergies and respiratory diseases, and immune disorders. In particular, the direct sales network established across Europe and country-specific sales strategies are cited as key competitive advantages.
A Celltrion official stated, “Since the pharmaceutical procurement environment and tender systems vary by country in Europe, tailored sales strategies that take into account the characteristics of each market are crucial,” adding, “We are maximizing the strengths of our direct sales system by flexibly responding to the market environment and demand in each country, centered on our local subsidiaries.”
The spokesperson added, “We are expanding the sales network established through our existing products to new products, while enhancing sales synergies based on our product portfolio spanning various therapeutic areas.”
Industry observers assess that the sales network established through existing products has accelerated the entry of new products into local markets. By proposing follow-up products to existing clients and leveraging experience with country-specific tender schedules and pricing structures in the sales of new products, the company has reduced the time and costs required for initial market penetration.
However, some analysts note that it remains to be seen whether these results will translate into sustained sales growth in Europe. This is because outcomes may vary depending on actual supply volumes following the contract and whether the contract is renewed.
A biotech industry official stated, “Leveraging the network of hospitals and purchasing organizations established through existing products for subsequent biosimilars can reduce the time to market and sales costs for new products,” but added, “We must also monitor actual supply volumes, whether contracts are renewed once competition intensifies, and whether subsequent hospital tenders are won.”